These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17222931)

  • 1. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.
    De Meerleer GO; Fonteyne VH; Vakaet L; Villeirs GM; Denoyette L; Verbaeys A; Lummen N; De Neve WJ
    Radiother Oncol; 2007 Feb; 82(2):160-6. PubMed ID: 17222931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
    J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.
    De Meerleer G; Fonteyne V; Meersschout S; Van den Broecke C; Villeirs G; Lumen N; Ost P; Vandecasteele K; De Neve W
    Radiother Oncol; 2008 Nov; 89(2):205-13. PubMed ID: 18771809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
    Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
    Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
    Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
    Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients.
    Ost P; Fonteyne V; Villeirs G; Lumen N; Oosterlinck W; De Meerleer G
    Eur Urol; 2009 Oct; 56(4):669-75. PubMed ID: 19501453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.